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Abstract: Bone metastases frequently occur in patients with advanced solid tumors, particularly 
breast and prostate cancers, and nearly all patients with multiple myeloma have some degree of 
skeletal involvement. The strides made in treating these primary tumors have extended median 
survival times and thereby increased patient risk for skeletal-related events (SREs), including 
pathologic fractures, spinal cord compression, need for palliative radiation therapy or surgery 
to bone, and hypercalcemia. Bisphosphonates, inhibitors of osteoclastic bone resorption that 
were ﬁ  rst established as treatment of osteoporosis, have been shown to prevent and/or delay 
SREs related to malignancy. The results of a large, randomized phase 3 study comparing 
zoledronic acid and pamidronate in breast cancer or multiple myeloma patients with osteolytic 
lesions showed that the incidence of SREs, time to ﬁ  rst SRE, and risk of developing a SRE 
were similar between treatment groups. However, in patients with solid tumors (excluding 
breast or prostate cancer) metastatic to the bone, only zoledronic acid has demonstrated clinical 
efﬁ  cacy. Although bone turnover marker levels, such as N-telopeptide of type I collagen, have 
been shown to correlate with clinical response, additional studies are needed to validate their 
ability to predict response to bisphosphonate therapy.
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Introduction
Osteoporosis, a skeletal condition common in postmenopausal women and aging 
men, is characterized by low bone mass, destruction of bone microarchitecture, 
and increased bone turnover resulting in decreased bone strength and consequent 
susceptibility to fractures.1,2 Osteoporotic fractures, such as fractures of the hip, 
vertebral body, and distal forearm, may lead to decreased quality of life (QOL), 
disability, and possibly death. In the last decade, bisphosphonates, compounds that 
inhibit osteoclastic bone resorption, have been the most signiﬁ  cant contribution to 
the advancement in osteoporosis treatment; clinical trials have demonstrated a reduc-
tion in vertebral fractures of 40% to 50% and nonvertebral fractures (including hip 
fractures) of 20% to 40%.1,3 Bisphosphonates approved by the United States Food 
and Drug Administration (FDA) for the prevention and/or treatment of osteoporosis 
include alendronate, alendronate plus vitamin D, ibandronate, risedronate, risedro-
nate with calcium, and zoledronic acid.4–10 Because their bioavailability is quite 
low, oral agents usually require daily or weekly administration (with the exception 
of ibandronate, which may be administered monthly) that can contribute to low 
patient compliance rates.6–9 Intravenous (IV) bisphosphonates may be administered 
less frequently (eg, on a monthly, quarterly, or yearly basis).6,10–12 In general, patient 
compliance rates with prescribed IV bisphosphonate regimens are higher than with 
oral bisphosphonates.Drug Design, Development and Therapy 2009:3 28
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In addition to osteoporosis, bisphosphonates have been 
used to prevent and/or treat cancer-related bone compli-
cations.3,13 Patients who develop bone metastases are at 
increased risk for developing skeletal-related events (SREs), 
such as intractable bone pain requiring opioid analgesics 
or palliative radiation therapy, pathologic fractures, spinal 
cord compression, a need for surgery, and hypercalcemia of 
malignancy (HCM).14 SREs are a consequence of excessive 
bone metabolism, primarily bone resorption, which charac-
terizes malignant bone lesions.3 Local bone pain requiring 
radiation therapy and pathologic fractures are the most com-
monly reported SREs.3
As a result of advancements in the primary treatment of 
several solid tumors and hematologic malignancies, patients 
are surviving longer, placing them at an increased risk for 
developing bone metastasis and SREs that may complicate 
their clinical course, adversely affect QOL, and increase 
medical costs.14–16 Bone metastases are particularly preva-
lent in patients with advanced metastatic breast or prostate 
cancers, affecting approximately 70% of patients.3 Although 
observed less frequently, bone metastases also occur in 
patients with lung, kidney, and thyroid tumors.17 Nearly all 
patients with advanced multiple myeloma (MM) develop 
bone involvement during the course of their disease since 
this malignancy colonizes in the bone marrow.14,18
Metastatic bone disease
Under normal circumstances, bone homeostasis is achieved 
through balanced resorption of old bone by osteoclasts and for-
mation of new bone by osteoblasts.19 Metastatic bone disease 
alters the normal bone remodeling process by causing osteo-
lytic bone destruction and abnormal osteoblastic bone forma-
tion, often with one process more dominant than the other, 
resulting in an imbalance in normal bone homeostasis.18–20 
Although historically bone metastases from breast cancer or 
MM have been characterized as osteolytic lesions and prostate 
cancer bone metastases have been primarily osteoblastic in 
nature, recent evidence suggest that both bone processes are 
present in many patients.18,20 Without bisphosphonate treat-
ment, it is estimated that patients with bone metastases from 
advanced cancer will experience, on average, 2 to 4 SREs per 
year.17 Thus, bone complications of cancer are a considerable 
clinical concern, and preventing or delaying the occurrence 
of such events is an important treatment objective. Although 
palliation has traditionally been the primary goal of therapy, 
the introduction of bisphosphonates has afforded oncologists 
with an effective therapeutic option for preventing and/or 
treating SREs associated with bone metastases.
Mechanism of action 
of bisphosphonates
Because of their ability to diminish bone resorption and 
subsequently normalize calcium levels, prevent development 
of new osteolytic lesions, and reduce the risk of fractures, 
bisphosphonates are the treatment of choice for skeletal 
complications of malignancy.21 Bisphosphonates are pyro-
phosphate analogs that preferentially bind to bone at sites 
of active metabolism, are released from the bone matrix 
during bone resorption, and inhibit osteoclast activity and 
survival.3,21 Variable side chains determine the potency and 
side effect proﬁ  le of each agent.21 These compounds can be 
grouped into two classes according to their chemical structure 
and molecular mechanism of action (Figure 1).22 The newer 
nitrogen (N)-containing, second- or third-generation com-
pounds, including alendronate, ibandronate, pamidronate, 
risedronate, and zoledronic acid, inhibit the enzyme farnesyl 
diphosphate synthase in the cholesterol mevalonate pathway 
and thereby suppress osteoclast-mediated bone resorption, 
whereas the non – N-containing, ﬁ  rst-generation bisphospho-
nates, such as clodronate, etidronate, and tiludronate, induce 
osteoclast apoptosis via metabolism into cytotoxic analogues 
of adenosine 5’-triphosphate.21,23,24 The N-containing agents 
are more potent than the non – N-containing bisphosphonates, 
inhibiting bone resorption at micromolar concentrations.3 
Only IV zoledronic acid and IV pamidronate are approved 
by the FDA for cancer-related indications.25,26 In Europe, oral 
clodronate, IV pamidronate, and oral and IV ibandronate have 
received regulatory approval for patients with bone metasta-
ses secondary to breast cancer.3,27 Only zoledronic acid has 
received US and European approval for the treatment of bone 
metastases independent of the primary tumor type.25,28
Evaluating efﬁ  cacy 
of bisphosphonates
Developing composite end points of similar clinical sig-
niﬁ  cance may be appropriate when the clinical beneﬁ  t of a 
drug is multifaceted as is the case with bisphosphonates.29 
Using a SRE as a quantiﬁ  able clinical end point was ﬁ  rst 
applied to studies assessing pamidronate for prevention of 
SREs. This end point included one or more of the following: 
pathologic fracture, radiation therapy for local pain, surgery 
to stabilize near-fractures, or spinal cord compression. Subse-
quently, SREs were used as the primary end points for most 
of the trials assessing a bisphosphonate for this indication. 
However, the deﬁ  nition or names for SREs have differed 
slightly between studies (see Tables 1–4), sometimes being Drug Design, Development and Therapy 2009:3 29
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referred to as skeletal complications or bone events.30–55 
Furthermore, HCM has been excluded from the deﬁ  nition 
of a SRE in some trials because bisphosphonates have been 
shown to be effective for the treatment of HCM before stud-
ies investigating bisphosphonates as preventive therapy for 
SREs were developed.31,56
Several clinical studies designed to evaluate bisphospho-
nates to prevent skeletal complications have demonstrated 
clinical beneﬁ  t. This article reviews the results of clinical 
studies assessing bisphosphonates as prevention and/or 




Clinical trial results show that bisphosphonates reduce the 
occurrence of skeletal complications in patients with breast 
cancer and bone metastases (Table 1).30–42 Based on the 
results of two randomized, placebo-controlled clinical stud-
ies in patients with osteolytic bone metastases from breast 
cancer being treated with either chemotherapy or hormonal 
therapy, IV pamidronate was approved by the FDA for pre-
venting SREs.35,37 Pamidronate (90 mg administered IV over 
2–4 hours q 3–4 weeks) signiﬁ  cantly prolonged the time to the 
ﬁ  rst SRE and reduced the overall incidence of SREs for up to 
2 years (see Table 1).35–38 In another placebo-controlled trial 
of breast cancer patients with at least one osteolytic lesion, 
zoledronic acid signiﬁ  cantly lowered the risk of SREs by 39% 
(p = 0.027), reduced the proportion of patients experiencing 
a SRE at 1 year by 20% (29.8% vs 49.6%, p = 0.003), and 
signiﬁ  cantly prolonged the time to ﬁ  rst SRE excluding HCM 
(median not reached vs 364 days, p = 0.007).33 Only one study 
has directly compared zoledronic acid with pamidronate 
(see Table 1).30,31 This large, randomized phase 3 study was 
designed to demonstrate the equivalence of zoledronic acid 
and pamidronate in reducing the incidence of SREs in patients 
with breast cancer or MM. Among the breast carcinoma 
stratum, the overall incidence of SREs other than HCM was 
comparable between the two study groups.31 The median time 
to ﬁ  rst SRE was also similar; however, in patients receiving 
hormonal therapy for breast cancer, zoledronic acid 4 mg IV 
signiﬁ  cantly delayed the time to ﬁ  rst SRE (415 vs 370 days; 
p = 0.047). Oral and IV ibandronate have also been evalu-
ated in breast cancer patients with metastatic bone disease; 
compared with placebo, both formulations of ibandronate 
(6 mg IV and 50 mg oral) have signiﬁ  cantly reduced the 
Figure 1 The structure of simple and nitrogen-containing bisphosphonates. Reprinted with permission from Russell RG. Bisphosphonates: mode of action and pharmacology. 
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proportion of patients with an on-study SRE and delayed 
the time to ﬁ  rst SRE (see Table 1).39,40 Oral clodronate also 
appears to reduce the rate and delay onset of SREs, and may 
reduce bone pain (see Table 1).41,42 Neither of these drugs, 
however, has been directly compared with zoledronic acid 
or pamidronate in this setting.
IV bisphosphonates are recommended for the preven-
tion of skeletal complications in breast cancer patients with 
bone metastases. Treatment guidelines from the American 
Society of Clinical Oncology (ASCO) recommend either 
IV pamidronate (90 mg) or IV zoledronic acid (4 mg) every 
3 to 4 weeks for patients with radiographic evidence of bone 
destruction; the panel concluded that there is insufﬁ  cient 
evidence to recommend one bisphosphonate over the other.57 
The National Comprehensive Cancer Network (NCCN) 
recommends either IV zoledronic acid or IV pamidronate 
for patients with bone metastases secondary to breast cancer 
as well.58 However, the NCCN guidelines suggest that 
zoledronic acid may be superior to pamidronate therapy for 
treating osteolytic metastases from breast cancer. Neither 
clodronate nor ibandronate were recommended; clodronate 
is not commercially available in the US, and ibandronate 
does not have a cancer-related FDA indication. Moreover, 
the Cochrane Breast Cancer Review Group has reported 
the results of their meta-analysis of 21 randomized trials 
evaluating bisphosphonates; in 9 studies, bisphosphonates 
reduced the risk of skeletal complications by 17% compared 
with placebo or no bisphosphonate (relative risk [RR] 0.83; 
95% conﬁ  dence interval [CI], 0.78–0.89; p = 0.00001).59 
Like the ASCO panel, the authors concluded that zoledronic 
acid appears to have equivalent efﬁ  cacy when compared 
with pamidronate.
Prostate cancer
Although prostate cancer is most commonly associated 
with osteoblastic lesions, increased osteoclastic activity 
also disrupts normal bone metabolism when prostate cancer 
invades the skeleton.60 Thus, inhibition of bone resorp-
tion by bisphosphonates may be beneﬁ  cial for osteoblastic 
metastases. Several bisphosphonates have been evaluated 
in patients with prostate cancer and metastatic bone dis-
ease, but only zoledronic acid has been shown to decrease 
SREs (Table 2).43–46 In a randomized study, patients with 
hormone-refractory prostate cancer (HRPC) were treated 
for up to 2 years with zoledronic acid or placebo; zoledronic 
acid signiﬁ  cantly reduced the proportion of patients expe-
riencing at least one SRE (38% vs 49%, 95% CI, −20.2% 
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(488 vs 321 days, p = 0.009) compared with placebo.43,44 In 
this setting, pamidronate did not signiﬁ  cantly reduce the 
SRE rate or reduce bone pain compared with placebo (see 
Table 2).45 Compared with placebo, oral clodronate (2080 mg 
daily) improved bone progression-free survival (deﬁ  ned as 
the time from randomization to the development of symp-
tomatic bone metastases or death from prostate cancer) and 
the overall survival time; however, differences in these end 
points were not statistically signiﬁ  cant.46 Bone progression-
free survival is similar to SRE except that it includes only 
symptomatic events rather than also including asymptomatic 
events (eg, metastasis identiﬁ  ed on bone scan, asymptomatic 
vertebral fractures). The Cochrane Prostatic Diseases and 
Urologic Cancers Group has corroborated these ﬁ  ndings in 
its meta-analysis of 10 studies evaluating bisphosphonates 
in metastatic prostate cancer; compared with controls, 
bisphosphonates reduced the risk of skeletal events by 21% 
(odds ratio 0.79; 95% CI, 0.62–1.00; p = 0.05).61 Currently, 
risedronate and zoledronic acid are also being evaluated in 
patients with bone metastases from androgen-sensitive pros-
tate cancer.62,63 According to consensus guidelines from the 
NCCN, bisphosphonate therapy should be considered for all 
patients with HRPC; however, the panel does not recommend 
a speciﬁ  c bisphosphonate.60
Lung cancer and other solid tumors
Only zoledronic acid 4 mg has demonstrated signiﬁ  cant 
long-term clinical beneﬁ  ts in patients with bone metasta-
ses from a broad range of solid tumors (Table 3).47–50 In a 
randomized, placebo-controlled, phase 3 study assessing 
patients with lung cancer or other solid tumors (excluding 
breast or prostate cancer), zoledronic acid 4 mg signiﬁ  cantly 
reduced the proportion of patients developing at least one 
SRE, including HCM at 21 months (39% vs 48%, p = 0.039) 
and delayed the onset of skeletal complications (236 vs 
155 d, p = 0.009).47,48 Moreover, when HCM was included, 
zoledronic acid 4 mg reduced the risk of developing a SRE, 
including HCM, by 31% (hazard ratio, 0.693; p = 0.003) 
compared with placebo.48 Non – small cell lung cancer, renal 
cell carcinoma, and small cell lung cancer were the most 
common diagnoses of enrolled patients. Oral clodronate 
(1600 mg/day for 1 year) was also evaluated in patients 
with bone metastases from solid tumors poorly responsive 
to chemotherapy; clodronate did not signiﬁ  cantly reduce 
mean pain scores compared with placebo but signiﬁ  cantly 
reduced use of analgesics (p = 0.042).50 Ibandronate 6 mg 
IV, administered every 4 weeks for 9 months to patients with 
metastatic bone disease from colorectal cancer, signiﬁ  cantly 
reduced the proportion of patients who experienced SREs 
(39% vs 78%, p = 0.019) and delayed time to the ﬁ  rst SRE 
by at least 6 months (279 vs 93 days, p = 0.009) compared 
with placebo.49 Ibandronate has not been evaluated in other 
solid tumors. For bone metastases related to solid tumors 
other than breast or prostate cancer, zoledronic acid is the 
only bisphosphonate that has received worldwide regulatory 
approval.25 Consensus guidelines for the use of bisphospho-
nates for patients with lung cancer or other solid tumors 
(except breast and prostate cancer) are not available.64
Multiple myeloma
The long-term efﬁ  cacy and safety of bisphosphonate therapy 
for prevention of SREs in patients with advanced MM 
and osteolytic lesions is well established (Table 4).30,31,51–55 
In a randomized, placebo-controlled trial, pamidronate 
(90 mg IV administered over 4 hours q 4 weeks) signiﬁ  cantly 
delayed the onset (p = 0.016) and reduced the incidence of 
skeletal complications (p = 0.016) for up to 21 months.51.52 
Consequently, a large, international, randomized, phase 3 
trial was designed to demonstrate equivalence (deﬁ  ned as 
difference in SRE rate of less than 8%) between either 
4 or 8 mg zoledronic acid and standard-dose pamidronate 
(90 mg).30,31 Because of renal safety concerns, the proto-
col was amended to reduce zoledronic acid from 8 mg to 
4 mg.30 After 25 months of follow-up, the percentage of MM 
patients who developed a SRE excluding HCM (47%, 4 mg 
zoledronic acid vs 51%, pamidronate), the median time to 
ﬁ  rst SRE including HCM (380 vs 286 days, p = 0.538), and 
the risk of developing a skeletal complication (RR, 0.932; 
p = 0.593) were similar between the treatment groups.31 
Most of these studies assessed zoledronic acid administered 
every 3 to 4 weeks; however, because of its long half-life 
and evidence supporting the use of longer dosing intervals 
for other indications, less frequent dosing (every 12 wk) is 
being evaluated.  65 Furthermore, oral clodronate (1600 mg 
daily) has established its ability to signiﬁ  cantly reduce the 
incidence of nonvertebral and vertebral fractures compared 
with placebo in MM patients.54 Long-term follow-up indicates 
that clodronate treatment may also prolong survival time in 
patients without overt vertebral fractures at diagnosis.55 Iban-
dronate has not been shown to reduce skeletal complications 
in this patient population.53
ASCO recently released an update to their clinical prac-
tice guidelines for the role of bisphosphonates in MM.66 For 
MM patients who have radiographic evidence of osteolytic 
bone destruction or spinal compression, ASCO recommends 
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at least 2 hours or zoledronic acid 4 mg IV delivered over 
15 minutes every 3 to 4 weeks for a period of 2 years. IV or 
oral clodronate is an alternative in other countries, but it is 
not commercially available in the United States.
Duration of therapy
A consensus has not been reached regarding the appropriate 
duration of bisphosphonate therapy. Most studies of bisphos-
phonates in cancer patients with bone metastases did not 
treat patients beyond 2 years. However, ASCO has tried to 
place some clarity on the issue in both their clinical practice 
guidelines for patients with breast cancer and MM.57,66 In 
patients with breast cancer metastatic to bone, ASCO advises 
to continue bisphosphonates until evidence of a progressive 
decline in performance status develops, even in the presence 
of SREs.57 No evidence addressing the consequences of dis-
continuing bisphosphonate therapy after developing a SRE in 
breast cancer patients exists. Among patients with osteolytic 
metastases secondary to MM, 2 years of bisphosphonate 
therapy is recommended.66 After 2 years, treating physi-
cians should consider treatment discontinuation if the MM 
is responding to therapy or is stable. Guidelines addressing 
duration of therapy in other solid tumors are not available.
Bone turnover markers
Investigators frequently assess markers of bone turnover 
as secondary end points in bisphosphonate studies. Bio-
chemical markers of bone metabolism are indicative of either 
bone formation or bone resorption and may help identify 
patients likely to respond to and beneﬁ  t from bisphospho-
nate therapy.67 N-telopeptide of type I collagen (NTX) is 
of particular interest; patients with bone metastases and 
elevated NTX levels in urine have a signiﬁ  cantly increased 
risk of SREs, disease progression, and death compared with 
patients with low NTX levels.68 In addition, urinary NTX 
normalization with pamidronate treatment has been linked 
with delays in bone lesion progression and a trend toward 
fewer fractures.69 Thus, NTX may be useful for monitoring 
therapeutic response to bisphosphonate therapy. However, 
because of the lack of sufﬁ  cient, rigorous, prospective trials 
validating this approach, ASCO’s clinical practice guide-
lines recommend that the use of these markers be conﬁ  ned 
to research protocols; currently, they should not be used in 
routine clinical practice.57,66
Conclusion
Skeletal complications are a major source of cancer-related 
morbidity. In patients with bone metastases, bisphosphonates 
have become the standard of care for preventing or delaying 
SREs. In patients with breast cancer or MM involving bone, 
zoledronic acid and pamidronate were comparable in their 
ability to decrease the incidence of SREs and delay the onset 
of skeletal events. In patients with solid tumors (except 
breast cancer) that metastasize to the bone, only zoledronic 
acid has been proven effective; ibandronate is effective 
in colorectal cancer. Despite their impressive efﬁ  cacy in 
the prevention of skeletal complications associated with 
malignancy, several questions related to bisphosphonate 
use remain. Studies are ongoing to evaluate the appropriate 
duration of therapy, validate the usefulness of bone markers 
in predicting response to therapy, understand management 
of toxicities such as osteonecrosis of the jaw, and determine 
the most appropriate and cost-effective time to initiate 
bisphosphonate therapy.70
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